Drug intelligence / Profile preview

GAIA-122

Development stage: Preclinical
Lead developer: GAIA BioMedicine
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

GAIA-122 is a preclinical-stage, antibody-armed NK-like cell therapy being developed by GAIA BioMedicine for the treatment of undisclosed tumors. The therapy utilizes GAIA's proprietary NK-like cells—highly activated and expanded natural killer cells—that are 'armed' with a monoclonal antibody targeting an undisclosed tumor-associated antigen, referred to as Target B. This approach is designed to enhance the specificity and cytotoxic potency of the NK-like cells against tumor cells expressing the target antigen, leveraging the innate anti-tumor activity of NK cells combined with antibody-mediated targeting.

Beyond the preview

Go deeper on GAIA-122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GAIA-122.

Explore the full profile